Simufilam

Simufilam (PTI-125) is an orally active FLNA modulator. Simufilam restores NMDAR signaling and Arc expression. Simufilam inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, improves insulin sensitivity, reduces Aβ42-induced neuroinflammation and tau protein hyperphosphorylation. Simufilam can be used for research of Alzheimer's disease[1][2][3].

Product Specifications

CAS Number

[1224591-33-6]

Product Name Alternative

PTI-125

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Amyloid-β; iGluR; mTOR; Tau Protein

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling; PI3K/Akt/mTOR

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/simufilam.html

Purity

98.08

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1N(CC2=CC=CC=C2)C3(CCN(C)CC3)NC1

Molecular Formula

C15H21N3O

Molecular Weight

259.35

Precautions

H302, H315, H319, H335

References & Citations

[1]Wang HY, et al. Simufilam suppresses overactive mTOR and restores its sensitivity to insulin in Alzheimer's disease patient lymphocytes. Front Aging. 2023 Jun 29;4:1175601.|[2]Wang HY, et al. Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A. J Neurosci. 2012 Jul 18;32 (29) :9773-84.|[3]Wang HY, et al. PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer's disease pathogenesis. Neurobiol Aging. 2017 Jul;55:99-114.